Response Genetics Inc. announced that it has extended its agreement with Taiho Pharmaceutical Co. Ltd. to provide testing and analyses services for specified molecular markers used in research, diagnosis and the therapeutic treatment of cancer. Under the terms of the agreement, Response Genetics will receive a minimum of $950,000 for services provided during the extended term of January 1 through December 31, 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2016 | Response Genetics, Inc Bankruptcy Case Dismissed | CI |
2016 | Motion for Case Dismissal Filed for Response Genetics, Inc | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 38 | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- RGDXQ Stock
- News Response Genetics, Inc
- Response Genetics, Inc Renews Agreement with Taiho Pharmaceutical Co., Ltd. to Provide Molecular Analyses for Cancer